Skip to main content
Sharp Therapeutics Corp. logo

Sharp Therapeutics Corp. — Investor Relations & Filings

Ticker · SHRX ISIN · CA8200092077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-04-24 Capital/Financing Update
Country CA Canada
Listing TSXV SHRX

About Sharp Therapeutics Corp.

https://sharptx.com/

Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for hereditary disorders. The core business involves leveraging its proprietary Disco(tm) platform, which integrates high-speed laboratory automation with advanced computational methods, including molecular-physics and mathematical modeling, to rapidly identify small molecules that correct protein defects. This approach is designed to deliver first-choice oral medicines for genetic diseases, offering advantages over traditional biologics. Sharp focuses on monogenic diseases to utilize an accelerated and de-risked clinical development path. Current lead programs address high unmet needs in Gaucher Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Material Change Report (Form 51-102F3) disclosing the completion of a private placement of unsecured convertible notes and a letter agreement for a future share purchase commitment, along with changes to the company’s reporting frequency. This clearly concerns the company’s capital raising and financing activities rather than an earnings release, management discussion, or full financial report. Therefore, it fits the Capital/Financing Update category (CAP).
2026-04-24 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 1% confidence The document is a mandated securities regulatory filing (Form 72-503F) reporting an exempt distribution of convertible notes (i.e., a financing issuance) under Canadian securities law. It is not a broad annual or quarterly report, call transcript, or earnings release. It is not merely an announcement of publication but the actual regulatory report itself. It does not fit specific categories like Board changes, dividends, or M&A. Therefore, it is best classified under the general Regulatory Filings category (RNS).
2026-04-24 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a corporate press release primarily announcing fourth quarter financial results (key highlights only) for the year ended December 31, 2025, which aligns with an Earnings Release. Although it also includes a financing transaction (closing of a convertible note offering) and a governance change (adoption of semi-annual reporting), the main focus is on the announcement of quarterly results. The length (over 9,000 characters) and the inclusion of forward-looking statements confirm it is the actual earnings release rather than a brief Regulatory Filing or a Report Publication Announcement. FY 2025
2026-04-18 English
Other material contracts - English.pdf
Investor Presentation Classification · 1% confidence The document is a detailed "Client Brochure" from BMO outlining the terms, features, and mechanics of its Principal-at-risk Notes. It contains investment highlights, product structure, hypothetical payoff scenarios, observation dates, and references to a prospectus, all characteristic of marketing presentation materials for investors rather than an official regulatory filing, earnings release, or annual report. It is not a simple factsheet (FS), regulatory announcement (RNS/RPA), or financing announcement (CAP) but rather a detailed investor presentation. Therefore, the correct classification is Investor Presentation (IP).
2026-04-18 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a binding letter agreement between STX Partners and Sharp Therapeutics detailing the terms of a USD 15 million equity financing round (number of shares, price per share, closing conditions, hold period, use of proceeds). It is not an AGM, proxy, regulatory announcement, or earnings release, but rather a private commitment to lead an equity financing. This aligns with the definition of a Capital/Financing Update (CAP).
2026-04-18 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a binding letter agreement committing STX Partners to lead a $15 million equity financing round by purchasing newly issued shares. It details fundraising terms, share price, use of proceeds, and legal conditions. This clearly constitutes an update on company financing activities rather than an annual report, earnings release, or regulatory notice. Therefore it falls under Capital/Financing Update (CAP).
2026-04-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.